Alkermes
Price & Volume
Stats
See moreOpen | $29.97 |
Previous Close | $30.10 |
Day Range | $29.94-$30.34 |
52W Range | $22.90-$32.88 |
Market Cap | $4.8B |
Shares Short | 10M |
Financials
See moreRevenue (12 Mos) | $1.5B |
Revenue Growth (YoY) | -0.7% |
Gross Profit (12 Mos) | $1.2B |
Diluted EPS | $2.29 |
News
See moreYahoo Finance • 5 months ago
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
Yahoo Finance • 5 months ago
We Ran A Stock Scan For Earnings Growth And Alkermes (NASDAQ:ALKS) Passed With Ease
Yahoo Finance • 9 months ago
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Yahoo Finance • 11 months ago
Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript
About
CEO | Mr. Richard F. Pops |
CFO | Mr. Iain Michael Brown |
Address | Connaught House, Dublin, Ireland, D04 C5Y6 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 2,100 |
